Company presentationDr. Ronald van der GeestSeptember 2012
The Long Road to a New   Medicine...                                                           NDA/MMA                    ...
Better medicines, badly needed  Continuous re-invention of the process
Our focusProvide innovative development solutions for   small to full-size life science companies,     scientific and gove...
Operational model                       Project team                       • Project lead          3D-PXC:      • Clinical...
Project models          Model 1                          Model 2                          Model 3Stand-alone projects, bas...
Differentiating factorsFocus on creation of added value in 3 Dimensions:                 Time, Cost & Risk
Differentiating factorsProgram II (1996)       Program I (2002)        Program III (2008)4 phase I trials        6 phase I...
Project examples• Nasal spray development for  conscious sedation and epilepsy• Develop novel companion  diagnosytic strat...
Clients - examples
Contact detailsVisiting Address:Maidstone 48A, 5026 SK TilburgTel:    +31 (0)13 534 8272Website:        www.3d-pxc.com    ...
Upcoming SlideShare
Loading in …5
×

3D-PharmaXchange by Ronald van der Geest

747 views
600 views

Published on

LTL presents at BioVille: CRO solutions, Six contract research organisations present their services

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
747
On SlideShare
0
From Embeds
0
Number of Embeds
269
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

3D-PharmaXchange by Ronald van der Geest

  1. 1. Company presentationDr. Ronald van der GeestSeptember 2012
  2. 2. The Long Road to a New Medicine... NDA/MMA Clinical Data AnalysisFull Development Registration Studies in 100-300 Candidate Medicine Tested in Patients (Phase II) 3-10,000 Patients (Phase III) Large Amounts of Candidate Medicine Extensive Studies in Healthy Synthesized Safety Volunteers (Phase I) Studies Exploratory Development Formulations Developed Candidate Early Safety Studies Synthesis Project Team Screening and Plans of Compounds Discovery
  3. 3. Better medicines, badly needed Continuous re-invention of the process
  4. 4. Our focusProvide innovative development solutions for small to full-size life science companies, scientific and government institutes
  5. 5. Operational model Project team • Project lead 3D-PXC: • Clinical IP, Development • Formulation Capital, expertise • Regulatory Management • Toxicology • Ad hocsNetwork & expertise
  6. 6. Project models Model 1 Model 2 Model 3Stand-alone projects, based on Full project management from Insertion of lacking expertiseprior and mutually agreed input start-to-finish, often in parallel in on-going projects, both and output requirements to in-house projects temporary and medium term
  7. 7. Differentiating factorsFocus on creation of added value in 3 Dimensions: Time, Cost & Risk
  8. 8. Differentiating factorsProgram II (1996) Program I (2002) Program III (2008)4 phase I trials 6 phase I trials 2 phase I trials1 phase II trial 0 phase II trials 1 phase II trial2 phase III trials 2 phase III trials2 open label trialsdevelopment duration: development duration: development duration:Est. 5-6 yrs Est. 4 yrs Est. 2 yrsEst. budget: Est. budget: Budget:105 M 60 M 15 M
  9. 9. Project examples• Nasal spray development for conscious sedation and epilepsy• Develop novel companion diagnosytic strategy for high-end diagnostic company• Social Innovation in Life Sciences (SaILS) for Midden-Brabant aI LS• Development of a new chemical entity against incontinence S• Full coordination of approval-to-launch process for early-stage biologics Biotech
  10. 10. Clients - examples
  11. 11. Contact detailsVisiting Address:Maidstone 48A, 5026 SK TilburgTel: +31 (0)13 534 8272Website: www.3d-pxc.com Ronald van der Geest, PhD +31 6 523 901 30 Ronald@3d-pxc.com

×